DR. NEIL WATTSON WAGLE, M.D.
Osteopathic Medicine at Francis St, Boston, MA

License number

Massachusetts 244653

Personal information

See more information about NEIL WATTSON WAGLE at radaris.com

Name

Address

Phone

Neil Wagle

107 Avenue Louis Pasteur, Boston, MA 02115

Professional information

See more information about NEIL WATTSON WAGLE at trustoria.com

Dr. Neil W Wagle, Boston MA - MD (Doctor of Medicine)

Specialties:

Internal Medicine

Address:

BRIGHAM & WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone), (617) 731-5453 (Fax)
BOSTON FAMILY DERMATOLOGY
1153 Centre St SUITE 5910, Jamaica Plain 02130
(617) 522-2779 (Phone), (617) 522-5698 (Fax)
75 Francis St, Boston 02115
(617) 732-5500 (Phone), (857) 307-1366 (Fax)

Languages:

English

Hospitals:

BRIGHAM & WOMENS HOSPITAL
75 Francis St, Boston 02115
75 Francis St, Boston 02115
BOSTON FAMILY DERMATOLOGY
1153 Centre St SUITE 5910, Jamaica Plain 02130
Brigham and Women's Hospital
75 Francis St, Boston 02115

Education:

Medical School
Harvard Med Sch
Graduated: 2007
Brigham And Women'S Hospital

Investment Analyst At Vision Capital Advisors

Location:

Greater Boston Area

Industry:

Medical Practice

Work:

Vision Capital Advisors May 2008 - Aug 2008 - Investment Analyst HDL Dynamic Laboratories Jan 2004 - May 2008 - Founder Pulmatrix Inc. Jan 2002 - Sep 2003 - Co-Founder

Education:

Harvard Business School 2007 - 2009
M.B.A. Harvard Medical School 2003 - 2007
M.D. Harvard University 1999 - 2003

Non-Invasive Treatment Of Disease Using Amphipathic Compounds

US Patent:

2005017, Aug 11, 2005

Filed:

Feb 11, 2005

Appl. No.:

11/057091

Inventors:

Neil Wagle - Brookline MA, US

International Classification:

A61K038/17

US Classification:

514002000

Abstract:

The present invention features a non-invasive system and method for delivering apolipoprotein, amphipathic compounds, and the like into the blood stream using pulmonary delivering. Apolipoprotein, amphipathic compounds, and the like is suspended in a solvent, preferably a saline solution. Next, the soluation is nebulized to form a plurality of droplets sized to reach the periphery of the lung. Once proximate the lung, the apolipoprotein, amphipathic compounds, and the like is dissolved through the lung interface and into the serum. Due to its physical and chemical properties, apolipoprotein A-I is effectively absorbed into the serum through the lung. The present invention can be used for the treatment of cardiovascular disease as well Alzheimer's Disease and other.

Phosphatidylcholine Transfer Protein Inhibitors

US Patent:

2012026, Oct 18, 2012

Filed:

Aug 17, 2010

Appl. No.:

13/390910

Inventors:

David Cohen - Chestnut Hill MA, US
Neil Wagle - Brookline MA, US
Gregory D. Cuny - Cambridge MA, US
Jun Xian - Sharon MA, US
Marcie Glicksman - Winchester MA, US
Ross L. Stein - Cambridge MA, US
Ekaterina Y. Shishova - Bryn Mawr PA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

A61K 31/505, A61K 31/44, A61K 31/472, C07C 335/26, A61K 31/17, C07D 295/155, A61K 31/5377, A61P 3/04, A61P 3/10, A61P 1/16, A61P 11/06, A61P 9/12, A61P 3/06, A61P 9/00, A61P 19/02, A61P 9/10, A61P 25/00, A61P 25/24, A61P 35/00, A61P 1/04, C07D 239/69

US Classification:

5142382, 544297, 514275, 514346, 514309, 564 23, 514584, 544160

Abstract:

This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.